Tokyo Tape
Sign in
← Sundrug

Quarterly report · Q2

9989.TEDINET S100SAP5
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥371.7bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥690.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥339.2bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥18.5bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥21.0bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥38.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥18.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥20.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥18.5bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥14.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥25.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥12.7bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥14.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥12.7bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥369.9bnat 2023-09-30Cons.Assets
Total assets¥360.7bnat 2023-03-31Cons.Assets
Total assets¥337.1bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥125.2bnat 2023-09-30Cons.Liabilities
Total liabilities¥124.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥244.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥236.3bnat 2023-03-31Cons.Net assets
Net assets / equity¥229.1bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥76.8bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥80.9bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥76.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥80.9bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥94.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥89.3bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥23.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥37.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥21.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥21.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥28.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥12.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥17.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥4.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥120.22023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥61.182023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥219.832022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥108.812022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥54.942022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥219.822022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥108.812022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio66.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio68.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥26.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥26.1bn
jpcrp040300-q2r_E03226-000Discount Storereportable segmentrevenue2023-04-01 → 2023-09-30¥155.0bn
jpcrp040300-q2r_E03226-000Discount Storereportable segmentrevenue external2023-04-01 → 2023-09-30¥155.0bn
jpcrp040300-q2r_E03226-000Discount Storereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥5m
jpcrp040300-q2r_E03226-000Discount Storereportable segmentsegment profit2023-04-01 → 2023-09-30¥7.5bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentrevenue2023-04-01 → 2023-09-30¥242.8bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentrevenue external2023-04-01 → 2023-09-30¥216.7bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥26.1bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentsegment profit2023-04-01 → 2023-09-30¥13.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥397.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥371.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥26.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.6bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥24.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥24.7bn
jpcrp040300-q2r_E03226-000Discount Storereportable segmentrevenue2022-04-01 → 2022-09-30¥143.9bn
jpcrp040300-q2r_E03226-000Discount Storereportable segmentrevenue external2022-04-01 → 2022-09-30¥143.9bn
jpcrp040300-q2r_E03226-000Discount Storereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5m
jpcrp040300-q2r_E03226-000Discount Storereportable segmentsegment profit2022-04-01 → 2022-09-30¥6.7bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentrevenue2022-04-01 → 2022-09-30¥220.0bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentrevenue external2022-04-01 → 2022-09-30¥195.3bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥24.7bn
jpcrp040300-q2r_E03226-000Drug Storereportable segmentsegment profit2022-04-01 → 2022-09-30¥11.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥363.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥339.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥24.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥18.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 479
ItemContextValueUnit
Capital stockPrior1YearInstant3931000000JPY
Capital stockCurrentQuarterInstant3931000000JPY
Capital surplusPrior1YearInstant7430000000JPY
Capital surplusCurrentQuarterInstant7496000000JPY
Retained earningsPrior1YearInstant230658000000JPY
Retained earningsCurrentQuarterInstant238867000000JPY
Treasury stockPrior1YearInstant-3940000000JPY
Treasury stockCurrentQuarterInstant-3893000000JPY
Shareholders equityPrior1YearInstant238080000000JPY
Shareholders equityCurrentQuarterInstant246401000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant82000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant122000000JPY
Revaluation reserve for landPrior1YearInstant-1805000000JPY
Revaluation reserve for landCurrentQuarterInstant-1805000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-58000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-50000000JPY
Valuation and translation adjustmentsPrior1YearInstant-1781000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-1733000000JPY
Subscription rights to sharesPrior1YearInstant29000000JPY
Subscription rights to sharesCurrentQuarterInstant－JPY
Net assetsPrior1YearInstant236328000000JPY
Net assetsCurrentQuarterInstant244667000000JPY
Liabilities and net assetsPrior1YearInstant360672000000JPY
Liabilities and net assetsCurrentQuarterInstant369884000000JPY
Net salesPrior1YTDDuration339223000000JPY
Net salesCurrentYTDDuration371707000000JPY
Cost of salesPrior1YTDDuration257026000000JPY
Cost of salesCurrentYTDDuration278757000000JPY
Gross profitPrior1YTDDuration82196000000JPY
Gross profitCurrentYTDDuration92949000000JPY
Selling general and administrative expensesPrior1YTDDuration63685000000JPY
Selling general and administrative expensesCurrentYTDDuration72340000000JPY
Operating incomePrior1YTDDuration18511000000JPY
Operating incomeCurrentYTDDuration20609000000JPY
Interest income noiPrior1YTDDuration60000000JPY
Interest income noiCurrentYTDDuration60000000JPY
Dividends income noiPrior1YTDDuration3000000JPY
Dividends income noiCurrentYTDDuration4000000JPY
Gain on donation of noncurrent assets noiPrior1YTDDuration112000000JPY
Gain on donation of noncurrent assets noiCurrentYTDDuration168000000JPY
Other noiPrior1YTDDuration100000000JPY
Other noiCurrentYTDDuration141000000JPY
Non operating incomePrior1YTDDuration275000000JPY
Non operating incomeCurrentYTDDuration374000000JPY
Interest expenses noePrior1YTDDuration15000000JPY
Interest expenses noeCurrentYTDDuration14000000JPY
Other noePrior1YTDDuration2000000JPY
Other noeCurrentYTDDuration15000000JPY
Non operating expensesPrior1YTDDuration17000000JPY
Non operating expensesCurrentYTDDuration30000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass